Switching the Manufacturer of Antiepileptic Drugs is Associated with Higher Risk of Seizures: A Nationwide Study of Prescription Data in Germany
Ann Neurol 84:918-925, Lang, J.D.,et al, 2018
Antiseizure Medications
Neurol 86:e187-e188, Karceski, S., 2016
Assessing Bioequivalence of Generic Antiepilepsy Drugs
Ann Neurol 70:221-228,192, Krauss, G.L.,et al, 2011
Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Arch Neurol 66:1417-1418, Hamiwka,L., 2009
Generic Substitution in the Treatment of Epilepsy: Case Evidence of Breakthrough Seizures
Neurol 71:525-530, Berg,M.J.,et al., 2008
Lower Phenytoin Serum Levels in Persons Switched from Brand to Generic Phenytoin
Neurol 63:1494-1496, Burkhardt,R.T.,et al, 2004
Effect of Food on Absorption of Dilantin Kapseals and Mylan Extended Phenytoin Sodium Capsules
Neurol 57 582-589,571, Wilder,B.J.,et al, 2001
Therapeutic Bioequivalency Study of Brand Name Versus Generic Carbamazepine
Neurol 42:1147-1153, Oles,K.S.,et al, 1992
Assessment:Generic Substitution for Antiepileptic Medication
Report of Therap & Tech Assess Subcomm, Neurol 40:1641-164390., , 1990
Generic Substitutions for Antiepileptic Drugs
Neurol 40:1647-1651, Nuwer,M.R.,et al, 1990
Generic Antiepileptic Drugs and Associated Medical Resource Utilization in the United States
Neurol 74:1566-1574, 1562, Labiner,D.M., et al, 2010
The Risks and Costs of Multiple-Generic Substitution of Topiramate
Neurol 72:2122-2129, Duh,M.S.,et al, 2009
The Value of Specifying Brand-Name Antiepileptic Drugs
Arch Neurol 66:1415-1416, 1418, Ng,Y., 2009
Clinical Consequences of Generic Substitution of Lamotrigine for Patients with Epilepsy
Neurol 70:2179-2186, LeLorier,J.,et al, 2008
Position Statement on the Coverage of Anticonvulsant Drugs for the Treatment of Epilepsy
Neurol 68:1249-1250,1245, Liow,K.,et al, 2007